title: Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial.
abstract: BACKGROUND
  Urinary tract infection (UTI) is a prevalent condition in women during their lifetime with a high rate of recurrence within 3-6 mo.
  
  
  OBJECTIVE
  Our aim was to investigate the efficacy and tolerability of the intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) in female patients with a history of recurrent UTI.
  
  
  METHODS
  We conducted a prospective, randomised, double-blind, placebo-controlled study comparing the intravesical instillation of HA-CS with placebo in women with recurrent UTI.
  
  
  METHODS
  Participants were randomised to receive 50 ml of sterile sodium HA 1.6% and CS 2.0% solution (IALURIL(®)) weekly for 4 wk and then monthly for 5 mo.
  
  
  METHODS
  The primary end point of the study was defined as the mean number of UTI per patient per year. Participants were evaluated addressing UTI status/urinary symptoms and with a general health-related quality-of-life (QoL) questionnaire at baseline and after 3, 6, 9, and 12 mo.
  
  
  CONCLUSIONS
  In the intention-to-treat analysis, 57 women were randomly allocated to HA-CS (n=28) or placebo (n=29). The UTI rate per patient per year at the end of the study (12 mo) (mean±SD: -86.6%±47.6 vs -9.6%±24.6; mean difference: 77%; 95% confidence interval, 72.3-80.8; p=0.0002) and the mean time to UTI recurrence (52.7±33.4 vs 185.2±78.7 d; p<0.001) were significantly reduced after treatment with HA-CS compared with placebo. Overall urinary symptoms and QoL measured by questionnaires significantly improved compared with placebo (Pelvic Pain and Urgency/Frequency questionnaire symptom score: 14.53±4.32 vs 9.88±6.77; p=0.004; SF-36 QoL score: 78.6±6.44 vs 53.1±4.72; p<0.001). No serious adverse event was reported.
  
  
  CONCLUSIONS
  Compared with placebo, HA-CS intravesical instillations significantly reduced UTI rate without severe side effects while improving symptoms and QoL over a 12-mo period in patients with recurrent UTI.
  
  
  BACKGROUND
  ISRCTN 76354426.
authors.affiliation: Urology Unit, Magna Graecia University of Catanzaro, Catanzaro, Italy. damiano@unicz.it
authors.forename: Rocco
authors.initials: R
authors.lastname: Damiano
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Quarto
authors.forename: Ilaria
authors.initials: I
authors.lastname: Bava
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ucciero
authors.forename: Renato
authors.initials: R
authors.lastname: De Domenico
authors.forename: Michele I
authors.initials: MI
authors.lastname: Palumbo
authors.forename: Riccardo
authors.initials: R
authors.lastname: Autorino
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D002809:Chondroitin Sulfates / Q000008:administration & dosage*; D003556:Cystitis / Q000188:drug therapy / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D010919:Placebos; D011788:Quality of Life; D055502:Secondary Prevention; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000517:prevention & control*; D055675:Viscosupplements / Q000008:administration & dosage*
chemical_list: D010919:Placebos; D055675:Viscosupplements; D006820:Hyaluronic Acid; D002809:Chondroitin Sulfates